Endpoint definition ↥ FinnGen phenotype data 321302 individuals Apply sex-specific rule None 321302 Check conditions None 321302 Filter registries None 0 Check pre-conditions, main-only, mode, ICD version None 0 Check minimum number of events None 0 Include endpoints I9_ATHSCLE I9_AORTDIS I9_AORTANEUR I9_OTHANEUR I9_ARTEMBTHR I9_ARTEMBTHRLOW I9_EMBTHROAOR 16762 FG_DOAAC Extra metadata Level in the ICD hierarchy C First used in FinnGen datafreeze DF2
FinnGen phenotype data 321302 individuals Apply sex-specific rule None 321302 Check conditions None 321302 Filter registries None 0 Check pre-conditions, main-only, mode, ICD version None 0 Check minimum number of events None 0 Include endpoints I9_ATHSCLE I9_AORTDIS I9_AORTANEUR I9_OTHANEUR I9_ARTEMBTHR I9_ARTEMBTHRLOW I9_EMBTHROAOR 16762 FG_DOAAC Extra metadata Level in the ICD hierarchy C First used in FinnGen datafreeze DF2
Similar endpoints ↥ List of similar endpoints to Diseases of arteries, arterioles and capillaries (FINNGEN) based on the number of shared cases. Broader endpoints: Diseases of arteries, arterioles and capillaries Cardiovascular diseases (excluding rheumatic etc) Diseases of the circulatory system Cardiovascular diseases Co-morbidities of interest (NEURO) Narrower endpoints: Atherosclerosis, excluding cerebral, coronary and PAD Aortic aneurysm Thoracic aortic aneurysm Abdominal aortic aneurysm (AAA) Arterial embolism and thrombosis Show all endpoint correlations
List of similar endpoints to Diseases of arteries, arterioles and capillaries (FINNGEN) based on the number of shared cases. Broader endpoints: Diseases of arteries, arterioles and capillaries Cardiovascular diseases (excluding rheumatic etc) Diseases of the circulatory system Cardiovascular diseases Co-morbidities of interest (NEURO) Narrower endpoints: Atherosclerosis, excluding cerebral, coronary and PAD Aortic aneurysm Thoracic aortic aneurysm Abdominal aortic aneurysm (AAA) Arterial embolism and thrombosis Show all endpoint correlations
Summary Statistics ↥ Key figures All Female Male ? X Number of individuals Using example data: ID phenocode age FG1 EXAMPLE_ENDPOINT 45 FG1 ENDPOINT_XYZ 46 FG1 DEATH 47 FG2 EXAMPLE_ENDPOINT 30 FG2 EXAMPLE_ENDPOINT 30.1 FG3 ENDPOINT_XYZ 50 In this example the number of individuals is 2, since only 2 unique individuals (FG1 and FG2) have EXAMPLE_ENDPOINT events. Number of individuals 16317 4634 11683 ? X Unadjusted prevalence Using example data: ID phenocode age FG1 EXAMPLE_ENDPOINT 45 FG1 ENDPOINT_XYZ 46 FG1 DEATH 47 FG2 EXAMPLE_ENDPOINT 30 FG2 EXAMPLE_ENDPOINT 30.1 FG3 ENDPOINT_XYZ 50 In this example the unadjusted prevalence is 66 %. The unadjusted prevalence is the number of individuals having an endpoint divided by the total number of individuals. Here: 2 unique individuals (FG1 and FG2) have EXAMPLE_ENDPOINT events 1 individual (FG3) has no EXAMPLE_ENDPOINT event So the unadjusted prevalence is 2 / 3 = 66 %. Unadjusted prevalence (%) 5.29 2.67 8.65 ? X Mean age at first event Using example data: ID phenocode age FG1 EXAMPLE_ENDPOINT 45 FG1 ENDPOINT_XYZ 46 FG1 DEATH 47 FG2 EXAMPLE_ENDPOINT 30 FG2 EXAMPLE_ENDPOINT 30.1 FG3 ENDPOINT_XYZ 50 In this example the mean age at first event is 37.5. The mean age at first event for EXAMPLE_ENDPOINT is computed by: selecting individuals having EXAMPLE_ENDPOINT: FG1 and FG2 for these individuals, taking the age of their first event of EXAMPLE_ENDPOINT: 45 for FG1 and 30 for FG2 computing the mean of these values So the mean age at first event is Mean(45, 30) = 37.5. Mean age at first event (years) 66.83 66.82 66.83 ? X Follow-up Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019. Absolute risk Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details. Hazard Ratio (HR) and 95% Confidence Interval (CI) Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1). Number of individuals (N) Number of individuals having the current endpoint and died during the follow-up time. Mortality Follow-up Absolute risk HR [95% CI] p N 1998–2019 0.06 5.07 [4.47, 5.74] <1e-100 5288 15 years 0.02 2.54 [2.27, 2.84] 2.4e-59 2064 5 years 0.00 4.57 [4.17, 5.02] <1e-100 1615 1 year - - - - Age distribution of first events Year distribution of first events Cumulative Incidence
Key figures All Female Male ? X Number of individuals Using example data: ID phenocode age FG1 EXAMPLE_ENDPOINT 45 FG1 ENDPOINT_XYZ 46 FG1 DEATH 47 FG2 EXAMPLE_ENDPOINT 30 FG2 EXAMPLE_ENDPOINT 30.1 FG3 ENDPOINT_XYZ 50 In this example the number of individuals is 2, since only 2 unique individuals (FG1 and FG2) have EXAMPLE_ENDPOINT events. Number of individuals 16317 4634 11683 ? X Unadjusted prevalence Using example data: ID phenocode age FG1 EXAMPLE_ENDPOINT 45 FG1 ENDPOINT_XYZ 46 FG1 DEATH 47 FG2 EXAMPLE_ENDPOINT 30 FG2 EXAMPLE_ENDPOINT 30.1 FG3 ENDPOINT_XYZ 50 In this example the unadjusted prevalence is 66 %. The unadjusted prevalence is the number of individuals having an endpoint divided by the total number of individuals. Here: 2 unique individuals (FG1 and FG2) have EXAMPLE_ENDPOINT events 1 individual (FG3) has no EXAMPLE_ENDPOINT event So the unadjusted prevalence is 2 / 3 = 66 %. Unadjusted prevalence (%) 5.29 2.67 8.65 ? X Mean age at first event Using example data: ID phenocode age FG1 EXAMPLE_ENDPOINT 45 FG1 ENDPOINT_XYZ 46 FG1 DEATH 47 FG2 EXAMPLE_ENDPOINT 30 FG2 EXAMPLE_ENDPOINT 30.1 FG3 ENDPOINT_XYZ 50 In this example the mean age at first event is 37.5. The mean age at first event for EXAMPLE_ENDPOINT is computed by: selecting individuals having EXAMPLE_ENDPOINT: FG1 and FG2 for these individuals, taking the age of their first event of EXAMPLE_ENDPOINT: 45 for FG1 and 30 for FG2 computing the mean of these values So the mean age at first event is Mean(45, 30) = 37.5. Mean age at first event (years) 66.83 66.82 66.83
? X Follow-up Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019. Absolute risk Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details. Hazard Ratio (HR) and 95% Confidence Interval (CI) Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1). Number of individuals (N) Number of individuals having the current endpoint and died during the follow-up time. Mortality Follow-up Absolute risk HR [95% CI] p N 1998–2019 0.06 5.07 [4.47, 5.74] <1e-100 5288 15 years 0.02 2.54 [2.27, 2.84] 2.4e-59 2064 5 years 0.00 4.57 [4.17, 5.02] <1e-100 1615 1 year - - - -
Follow-up Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.
Absolute risk Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.
Hazard Ratio (HR) and 95% Confidence Interval (CI) Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).
Number of individuals (N) Number of individuals having the current endpoint and died during the follow-up time.
Correlations ↥ Index endpoint: FG_DOAAC – Diseases of arteries, arterioles and capillaries (FINNGEN) GWS hits: 7
Survival analyses between endpoints ↥ Plot before Diseases of arteries, arterioles and capillaries (FINNGEN) after Diseases of arteries, arterioles and capillaries (FINNGEN) Loading survival analyses plot Table Loading survival analyses table Download CSV
Plot before Diseases of arteries, arterioles and capillaries (FINNGEN) after Diseases of arteries, arterioles and capillaries (FINNGEN) Loading survival analyses plot
Drugs most likely to be purchased after Diseases of arteries, arterioles and capillaries (FINNGEN) ↥ Download CSV